Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy
The US Food and Drug Administration (FDA) gave the green light on Wednesday to a new oral weight-loss medication developed by the Indianapolis-based pharmaceutical company Eli Lilly.
Known as orforglipron or brand name Foundayo, the once-daily tablet becomes the second GLP-1 drug in pill form to hit the market in a short span of time, arriving after Novo Nordisk’s Wegovy pill received approval in December.
Continue reading...
